These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8270267)

  • 1. Genetically engineered multi-component virus-like particles as veterinary vaccines.
    Pearson LD; Roy P
    Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():381-9. PubMed ID: 8270267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins.
    French TJ; Marshall JJ; Roy P
    J Virol; 1990 Dec; 64(12):5695-700. PubMed ID: 2173762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From genes to complex structures of bluetongue virus and their efficacy as vaccines.
    Roy P
    Vet Microbiol; 1992 Nov; 33(1-4):155-68. PubMed ID: 1336237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
    Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
    Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baculovirus multigene expression vectors and their use for understanding the assembly process of architecturally complex virus particles.
    Roy P; Mikhailov M; Bishop DH
    Gene; 1997 Apr; 190(1):119-29. PubMed ID: 9185857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the outer capsid protein VP5 of two bluetongue viruses, and synthesis of chimeric double-shelled virus-like particles using combinations of recombinant baculoviruses.
    Loudon PT; Hirasawa T; Oldfield S; Murphy M; Roy P
    Virology; 1991 Jun; 182(2):793-801. PubMed ID: 1850928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems.
    Roy P
    Intervirology; 1996; 39(1-2):62-71. PubMed ID: 8957671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
    Jiménez-Cabello L; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Illescas-Amo M; Benavides J; Moreno S; Marín-López A; Nogales A; Ortego J
    Front Immunol; 2024; 15():1440407. PubMed ID: 39072326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells.
    Belyaev AS; Roy P
    Nucleic Acids Res; 1993 Mar; 21(5):1219-23. PubMed ID: 8385313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.